A Rapoport

Summary

Publications

  1. doi request reprint Acute and prophylactic treatments for migraine: present and future
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurol Sci 29:S110-22. 2008
  2. doi request reprint Acute treatment of migraine: established and emerging therapies
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, Los Angeles, CA 90036, USA
    Headache 52:60-4. 2012
  3. doi request reprint The therapeutic future in headache
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, 239 South Orange Drive, Los Angeles, CA 90036, USA
    Neurol Sci 33:S119-25. 2012
  4. doi request reprint What happens to the old headache medicines?
    Alan M Rapoport
    David Geffen School of Medicine, UCLA, Los Angeles, CA 90036, USA
    Headache 52:701-6. 2012
  5. ncbi request reprint Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study
    A M Rapoport
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:821-6. 2007
  6. doi request reprint Medication overuse headache: awareness, detection and treatment
    Alan M Rapoport
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    CNS Drugs 22:995-1004. 2008
  7. doi request reprint Antimigraine drugs: new frontiers
    A Rapoport
    Department of Neurology, The David Geffen School of Medicine at UCLA in Los Angeles, 239 South Orange Drive, Los Angeles, CA 90036, USA
    Neurol Sci 30:S49-54. 2009
  8. pmc New acute treatments for headache
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurol Sci 31:S129-32. 2010
  9. doi request reprint Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine
    Alan M Rapoport
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    CNS Drugs 24:929-40. 2010
  10. doi request reprint New frontiers in headache therapy
    A Rapoport
    David Geffen School of Medicine at UCLA, 239 South Orange Drive, Los Angeles, CA 90036, USA
    Neurol Sci 32:S105-9. 2011

Detail Information

Publications27

  1. doi request reprint Acute and prophylactic treatments for migraine: present and future
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurol Sci 29:S110-22. 2008
    ..Some over-the-counter vitamins, minerals and herbs, used as preventive therapy in migraine, will be discussed. Future treatments in the pipeline will be briefly detailed...
  2. doi request reprint Acute treatment of migraine: established and emerging therapies
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, Los Angeles, CA 90036, USA
    Headache 52:60-4. 2012
    ..Migraine-specific medications such as triptans and non steroidal anti-inflammatory drugs should be used when possible. There are several promising medications and devices in the migraine pipeline...
  3. doi request reprint The therapeutic future in headache
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, 239 South Orange Drive, Los Angeles, CA 90036, USA
    Neurol Sci 33:S119-25. 2012
    ....
  4. doi request reprint What happens to the old headache medicines?
    Alan M Rapoport
    David Geffen School of Medicine, UCLA, Los Angeles, CA 90036, USA
    Headache 52:701-6. 2012
    ....
  5. ncbi request reprint Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study
    A M Rapoport
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:821-6. 2007
    ..To evaluate the efficacy and tolerability of zolmitriptan 5 mg and 10 mg nasal spray (ZNS) vs placebo in the acute treatment of cluster headache. Design/..
  6. doi request reprint Medication overuse headache: awareness, detection and treatment
    Alan M Rapoport
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    CNS Drugs 22:995-1004. 2008
    ..A long-term treatment plan, including behavioural therapy, migraine preventive medication and appropriate acute care therapy, may be optimal in treating patients with MOHs...
  7. doi request reprint Antimigraine drugs: new frontiers
    A Rapoport
    Department of Neurology, The David Geffen School of Medicine at UCLA in Los Angeles, 239 South Orange Drive, Los Angeles, CA 90036, USA
    Neurol Sci 30:S49-54. 2009
    ..There are also effective devices for therapy of migraine. A list of targets will be put forth and a small number of them will be described in greater detail in this paper...
  8. pmc New acute treatments for headache
    Alan M Rapoport
    The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurol Sci 31:S129-32. 2010
    ..Botulinum toxin therapy, although a preventive measure, will be mentioned at the end...
  9. doi request reprint Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine
    Alan M Rapoport
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    CNS Drugs 24:929-40. 2010
    ....
  10. doi request reprint New frontiers in headache therapy
    A Rapoport
    David Geffen School of Medicine at UCLA, 239 South Orange Drive, Los Angeles, CA 90036, USA
    Neurol Sci 32:S105-9. 2011
    ..I will not include transcranial magnetic stimulation, a 5-HT(1F) agonist, large conductance calcium-activated potassium channel openers, glial modulators or other medications and devices in early stages of development [1]...
  11. ncbi request reprint Which triptan for which patient?
    A M Rapoport
    Department of Neurology, Columbia University, New York, NY, USA
    Neurol Sci 27:S123-9. 2006
    ..New studies have looked at early treatment paradigms and result in better efficacy data, but are difficult to compare due to different endpoints...
  12. ncbi request reprint Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache
    M E Bigal
    Department of Neurology, Albert Einstein College of Medicine, USA
    Cephalalgia 22:432-8. 2002
    ..The Silberstein and Lipton system is easier to apply, and more parsimonious. These findings support revision of the IHS classification system to include chronic migraine...
  13. ncbi request reprint Cluster headache as a manifestation of intracranial inflammatory myofibroblastic tumour: a case report with pathophysiological considerations
    M E Bigal
    Department of Neurology, Albert Einstein College of Medicine and The New England Center for Headache, Stamford, CT 06902, USA
    Cephalalgia 23:124-8. 2003
    ....
  14. ncbi request reprint Intranasal medications for the treatment of migraine and cluster headache
    Alan M Rapoport
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    CNS Drugs 18:671-85. 2004
    ..Nevertheless, it is our opinion that nasal preparations increase therapeutic options and may result in faster response times and better efficacy than oral formulations and better patient satisfaction than injectable preparations...
  15. ncbi request reprint Mechanisms of action of the 5-HT1B/1D receptor agonists
    Stewart J Tepper
    New England Center for Headache, 778 Long Ridge Rd, Stamford, CT 06902 1251, USA
    Arch Neurol 59:1084-8. 2002
    ....
  16. ncbi request reprint Zolmitriptan (Zomig)
    Alan M Rapoport
    College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Expert Rev Neurother 4:33-41. 2004
    ..5-mg dose at early time points. The physician can now choose the optimum route of delivery of zolmitriptan to stop the headache, increase the likelihood of reducing disability and restore the patient to complete functionality...
  17. ncbi request reprint Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS)
    Frederick G Freitag
    Diamond Headache Clinic, Ltd, Chicago, IL 60614, USA
    Headache 47:519-30. 2007
    ....
  18. ncbi request reprint Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet
    Egilius L H Spierings
    Brigham and Women s Hospital, Boston, Massachusetts 02481 2106, USA
    CNS Drugs 18:1133-41. 2004
    ..To determine the speed of onset of headache response and duration of response with zolmitriptan 5 mg orally disintegrating tablet (ODT) in the acute treatment of migraine...
  19. ncbi request reprint The triptan formulations : how to match patients and products
    Alan M Rapoport
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    CNS Drugs 17:431-47. 2003
    ..Use of the methods outlined in this review in choosing a triptan for an individual patient is probably more likely to lead to migraine relief than making an educated guess as to which triptan is most appropriate...
  20. ncbi request reprint Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases
    Alan M Rapoport
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Headache 43:482-9. 2003
    ..To review the efficacy of naratriptan as preventive treatment in 27 patients with chronic migraine refractory to other commonly used preventive therapies...
  21. ncbi request reprint Patterns of use of triptans and reasons for switching them in a tertiary care migraine population
    Fred D Sheftell
    Department of Psychiatry, New York Medical College, NY, USA
    Headache 44:661-8. 2004
    ..To assess the reasons for switching triptans within migraine patients presenting to a specialty clinic...
  22. ncbi request reprint Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study
    Fred D Sheftell
    The New England Center for Headache, College of Medicine, Stanford, CT, USA
    Headache 45:1400-6. 2005
    ..To assess the efficacy, safety, and tolerability of daily naratriptan in the preventive treatment of transformed migraine (TM) refractory to previous first line therapies...
  23. ncbi request reprint Assessment of adverse events associated with triptans--methods of assessment influence the results
    Fred D Sheftell
    New York Medical College, Psychiatry, New York, NY, USA
    Headache 44:978-82. 2004
    ..However, the proportion of patients reporting side effects after any acute treatment may vary with regard to the method of assessment...
  24. ncbi request reprint The impact of topiramate on health-related quality of life indicators in chronic migraine
    David W Dodick
    Mayo Clinic College of Medicine, Department of Neurology, Scottsdale, AZ, USA
    Headache 47:1398-408. 2007
    ....
  25. ncbi request reprint Clinical pharmacology of the serotonin receptor agonist, zolmitriptan
    B Lee Peterlin
    Drexel University College of Medicine, 245 N 15th Street MS 423, Philadelphia, PA 19102, USA
    Expert Opin Drug Metab Toxicol 3:899-911. 2007
    ..Finally, the clinical application of zolmitriptan's use in patients is dicussed...
  26. ncbi request reprint Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period
    Chelsea A Meskunas
    Princeton University, Molecular Biology, NJ, USA
    Headache 46:766-72. 2006
    ..To evaluate the substances associated with medication overuse headache (MOH) in a headache center, over the course of the past 15 years...
  27. ncbi request reprint Ethical considerations in cluster headache research
    Stewart J Tepper
    The New England Center for Headache, 778 Long Ridge Road, Stamford, CT 06902, USA
    Curr Pain Headache Rep 6:47-51. 2002
    ..There is justification for studying attacks untreated, and even for precipitating these attacks. Placebo-controlled studies should only be undertaken for regulatory purposes; otherwise, active control should be used...